Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma.

MLA

Palacionyte, Jolita, et al. “Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma.” Diagnostics (2075-4418), vol. 14, no. 13, July 2024, p. 1345. EBSCOhost, https://doi.org/10.3390/diagnostics14131345.

APA

Palacionyte, J., Januskevicius, A., Vasyle, E., Rimkunas, A., Miliauskas, S., & Malakauskas, K. (2024). Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma. Diagnostics (2075-4418), 14(13), 1345. https://doi.org/10.3390/diagnostics14131345

Chicago

Palacionyte, Jolita, Andrius Januskevicius, Egle Vasyle, Airidas Rimkunas, Skaidrius Miliauskas, and Kestutis Malakauskas. 2024. “Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma.” Diagnostics (2075-4418) 14 (13): 1345. doi:10.3390/diagnostics14131345.